ERBB2 and gastroesophageal junction adenocarcinoma: Here, we report final analysis results from the DESTINY-Gastric06 trial, which evaluated the antitumor activity and safety of T-DXd in patients from China with HER2+ (immunohistochemistry [IHC] 3+/IHC 2+) advanced gastric or GEJ adenocarcinoma who had received two or more prior anticancer regimens.